DDMAC Slamming The Door On Open-Label Studies In Promotions
This article was originally published in The Pink Sheet Daily
Executive Summary
Nycomed gets a "notice of violation" letter for a flashcard that used open-label study data to make claims for its actinic keratoses treatment Solaraze (diclofenac).
You may also be interested in...
Otsuka Busulfex's Overall Survival Claim Does Not Survive CDER Advertising Scrutiny
Statistical analyses based on pivotal trial data and used to promote a drug must prove what they purport to prove, FDA's Office of Prescription Drug Promotion says in an NOV letter to Otsuka over a website for the leukemia drug Busulfex (busulfan).
Otsuka Busulfex's Overall Survival Claim Does Not Survive CDER Advertising Scrutiny
Statistical analyses based on pivotal trial data and used to promote a drug must prove what they purport to prove, FDA's Office of Prescription Drug Promotion says in an NOV letter to Otsuka over a website for the leukemia drug Busulfex (busulfan).
Convenience Claims, Squinty Risk Info For Arbor's Nitro Spray Draw FDA Letter
Professional sales aid and DTC brochure for Nitrolingual Pumpspray claim the product is superior to tablets without substantial evidence, DDMAC says.